Skip to content

Royan Institute

  Home arrow Reproductive
 arrow Research Groups arrow Pharmacogenetics
Pharmacogenetics PDF Print E-mail

Each individual can respond to the same doses of a drug in a different way, regarding to their own genetic variation patterns. Pharmacogenetics (PG) is the study or clinical testing of these genetic variations that gives rise to differing responses to drugs. PG also refers to genetic differences in metabolic pathways which can affect individual responses to drugs, both in terms of the therapeutic effect as well as adverse effects. Thus, PG studies are committed to select the best therapy for every patient with a minimum risk of complications. Furthermore, these studies allow the development of clinical tests based on the presence of profiles of biomolecules and other biological markers useful for routine diagnosis. However, interaction of Genetics, Epigenetics, Environmental and Lifestyle factors can explaining interindividual variability of drug response that is studied under name of precision medicine, which aims to improve health care by tailoring drug treatment to patients’ individual characteristics.
Since genetic variations play an important role in reproductive medicine, pharmacogenetics studies open a new field to modify and develop treatments for infertile couples. For instance, the application of PG to assisted reproductive techniques (ART) will help clinicians to improve the efficacy of hormone treatments that are being routinely applied during ART protocols. As an example, FSH- and estrogen-receptors are genetic markers involving controlled ovarian hyperstimulation as clinical studies have demonstrated that the p.N680S polymorphism of the FSH-receptor gene determines the less ovarian response to FSH stimulation in patients undergoing IVF. In women with homozygous Ser/Ser in their FSH-receptor, the FSH receptor appears to be more resistant to treatment. Therefore, genotyping of patients scheduled for ovarian stimulation could be an attractive tool to individualize FSH dosing according to genetic differences in ovarian sensitivity. Consequently, pharmacogenetics can assist physicians with prescribing medicine to achieve the controlled ovarian stimulation.
Our research outlines focus on genes that are involved in male/female infertility, particularly in ART-protocols response.

Group Leaders
Parvaneh Afsharian, PhD

Research Assistants

M Khosravi Far, MSc
Sh Zari Moradi, PhD student
A Poursadoghian, MSc
Z Chekini, MSc

B. Salmani (M.Sc Student)
M Gharebash (M.Sc Student)
H Ataei  (M.Sc Student)
Z Borandegi  (M.Sc Student)
N Mianmahaleh (M.Sc Student)
T Javid Tajrishi  (M.Sc Student)
S Sadati  (M.Sc Student)

  • Genetic and Pharmacogenetic aspects of ovulation induction in anovulatory women
  • Promoter assay of PII, I.3 and I.4 in Aromatase in human granulosa cells by luciferase assay
  • Gene expression and gene polymorphism study of the Estrogen receptor (ER) and Aromatase (CYP19) in infertile men referred to Royan Institute
  • Genetic aspects of endometriosis in patients referred to Royan Institute
  • The Analysis of PGR polymorphism (+331G/A) and Gene Expression levels in MMP-2,9 and PGR in endometrium tissue of women with Endometriosis Referring to Royan Institute
  • Genetic variation analysis of MIF in endometriosis patients referred to Royan Institue


Main Menu